サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1712513

神経診断学の世界市場：2025年～2033年

Global Neurodiagnostics Market - 2025-2033

出版日
ページ情報
英文 198 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
神経診断学の世界市場：2025年～2033年
出版日: 2025年04月22日
発行: DataM Intelligence
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の神経診断学の市場規模は、2024年に93億5,000万米ドルとなりました。同市場は、2033年には211億7,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは9.6%になると予測されています。

神経診断学とは、様々な診断技術やツールを使用した神経障害の特定、モニタリング、評価に焦点を当てた医療診断学の専門分野を指します。これらの技術は主に、脳、脊髄、末梢神経を含む神経系の機能、構造、全体的な健康状態を評価するために考案されたものです。

神経診断学には、電気生理学的検査と画像診断に基づく検査の両方が含まれるほか、場合によっては分子診断学も含まれ、ヘルスケアプロバイダーが中枢神経系や末梢神経系に関連する病態を診断するのに役立ちます。これらの疾患には、てんかん、アルツハイマー病、パーキンソン病、多発性硬化症、脳腫瘍、外傷性脳損傷（TBI）、睡眠障害などの神経疾患が含まれます。

神経診断における技術進歩の高まりが、神経診断学市場の成長を大きく促進しています。

技術進歩の高まりは、早期診断を可能にし、精度を向上させ、患者の転帰を改善し、診断ツールへのアクセシビリティを拡大することで、神経診断学市場の成長を大きく促進しています。これらの技術革新は、費用対効果の高いソリューション、患者ケアの改善、神経疾患の個別化治療計画の開発にもつながっています。このように、市場の主要企業や新興企業は、技術的に先進的な神経診断に注力しており、これが市場の成長をさらに後押ししています。

例えば、2025年4月、神経診断の開発企業であるCadwell Industriesは、特許出願中の超音波と筋電図（EMG）を同期させた最新のSierraソフトウェアのリリースを開始しました。Sierra Summit電気診断システムおよびSierra NMUS1統合超音波と組み合わせることで、このアップデートは電気生理学的データと超音波画像を1つの画面上でリアルタイムに一緒に表示します。これにより、針筋電図、ケモデナベーション、神経ブロック、ハイドロダイセクションの手技を支援することを目的としています。

さらに、2024年8月、Natus Medical Incorporatedは、自動的かつ包括的な臨床脳波判読が可能な世界初の人工知能モデル、autoSCOREを発表しました。autoSCOREアプリケーションは、てんかんに苦しむ数100万人の臨床転帰と治療価値を改善する可能性を秘めています。

神経診断手技に関連する高コストは、特に低所得地域や保険未加入の患者にとって、高度な診断ツールへのアクセスを制限し、市場成長の大きな障壁となっています。こうしたコストが最先端の神経診断技術の普及を妨げ、多くの神経疾患患者の診断と治療を遅らせています。

EEG、MRI、CTスキャン、PETスキャンなどの高度な神経診断技術の多くは、高価な機器とメンテナンスを必要とするため、小規模な病院や診療所では導入が困難です。特に脳波、MRI、CTスキャンなど定期的な診断検査が必要な患者にとっては、機器代に加え、検査そのものが経済的負担となります。例えば、ビデオ脳波モニタリングの場合、保険適用前で平均7万7,664米ドルかかります。

神経診断学市場が拡大し続ける中、こうしたコストの課題に対処することは、アクセシビリティとアフォーダビリティを向上させる上で極めて重要です。費用対効果の高い診断ツール、保険制度改革、高度な神経診断技術への政府資金援助といった解決策は、こうした障壁を克服し、今後数年間の市場成長を促進するために不可欠です。

当レポートでは、世界の神経診断学市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーとパイオニア
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向

第5章 神経診断学市場（製品タイプ別）

  • 診断機器
  • 試薬、消耗品、アクセサリー
  • ソフトウェアとアプリケーション

第6章 神経診断学市場（用途別）

  • てんかん
  • アルツハイマー病
  • パーキンソン病
  • 多発性硬化症
  • 睡眠障害
  • 頭痛障害
  • 脳卒中
  • 外傷性脳損傷（TBI）
  • 痴呆
  • その他

第7章 神経診断学市場（エンドユーザー別）

  • 病院
  • 神経科クリニック
  • 診断検査室
  • 在宅ケア
  • その他

第8章 神経診断学市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • GE HealthCare
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • FUJIFILM Holdings
  • Thermo Fisher Scientific Inc.
  • Compumedics Limited
  • Natus
  • Stratus
  • Canon Medical Systems USA, Inc.
  • Nihon Kohden Corporation

第11章 仮定と調査手法

第12章 付録

目次
Product Code: MI5095

The global neurodiagnostics market size reached US$ 9.35 billion in 2024 and is expected to reach US$ 21.17 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033.

Neurodiagnostics refers to a specialized branch of medical diagnostics that focuses on the identification, monitoring, and evaluation of neurological disorders through the use of various diagnostic techniques and tools. These techniques are primarily designed to assess the function, structure, and overall health of the nervous system, including the brain, spinal cord, and peripheral nerves.

Neurodiagnostics encompasses both electrophysiological and imaging-based tests, as well as molecular diagnostics in some cases, to assist healthcare providers in diagnosing conditions related to the central and peripheral nervous systems. These conditions include neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, traumatic brain injuries (TBI), and sleep disorders, among others.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurodiagnostics are significantly driving the neurodiagnostics market growth.

Rising technological advancements are significantly driving the growth of the neurodiagnostics market by enabling early diagnosis, improving accuracy, enhancing patient outcomes, and expanding accessibility to diagnostic tools. These innovations are also leading to cost-effective solutions, improved patient care, and the development of personalized treatment plans for neurological diseases. Thus, the key and emerging market players are focusing on technologically advanced neurodiagnostics, which are further boosting the growth of the market

For instance, in April 2025, Neurodiagnostics developer Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.

Additionally, in August 2024, Natus Medical Incorporated launched autoSCORE, the first-of-its-kind artificial intelligence model capable of automatic and comprehensive clinical EEG interpretation, providing accuracy on par with medical experts. The autoSCORE application has the potential to improve clinical outcomes and the value of care for the millions suffering from epilepsy.

High cost of neurodiagnostic procedures hampering the market growth

The high costs associated with neurodiagnostic procedures represent a significant barrier to market growth, limiting access to advanced diagnostic tools, especially in low-income regions and for underinsured patients. These costs hinder the widespread adoption of cutting-edge neurodiagnostic technologies, delaying diagnosis and treatment for many individuals with neurological conditions.

Many of the advanced neurodiagnostic technologies, such as EEG, MRI, CT scans, and PET scans, require expensive equipment and maintenance, making them difficult for smaller hospitals or clinics to afford. In addition to the costs of equipment, the procedures themselves can be financially burdensome for patients, particularly for those requiring regular diagnostic tests such as EEG, MRI, and CT scans. For instance, video EEG monitoring costs an average of $77,664 before insurance.

As the neurodiagnostics market continues to expand, addressing these cost challenges will be crucial for improving accessibility and affordability. Solutions like cost-effective diagnostic tools, insurance reforms, and government funding for advanced neurodiagnostic technologies are essential to overcome these barriers and drive market growth in the coming years.

Segment Analysis

The global neurodiagnostics market is segmented based on product type, application, end-user, and region.

Product Type:

The diagnostic equipment segment is expected to dominate the neurodiagnostics market with the highest market share.

The diagnostic equipment segment is the dominant segment in the neurodiagnostics market due to its crucial role in early detection, accurate diagnosis, and monitoring of neurological diseases. Technologies such as MRI, CT scans, EEG, and PET scans are essential tools for clinicians in diagnosing neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors.

The continued development of advanced imaging systems and non-invasive diagnostic tools has solidified the diagnostic equipment segment as the leading contributor to the market. Moreover, the novel product launches by key and emerging players by regulatory support are also boosting the segment growth.

For instance, in October 2024, Natus Medical Incorporated submitted an FDA 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Natus point-of-care EEG device. The rapid-deploy decision-support tool is designed to quickly help identify non-convulsive seizures (NCSs) and status epilepticus in acute care environments, supporting rapid intervention and streamlining treatment decisions to improve patient outcomes.

This point-of-care EEG system leverages Natus's leading NeuroWorks software platform to provide a seamless and familiar review experience with remote neurologist collaboration, 24/7 from any web browser. NeuroWorks EEG systems are trusted by more health systems and small practices around the world. With its unparalleled expertise in complex IT environments, Natus will utilize a leading cybersecurity-certified cloud platform to ensure patient data security.

Geographical Analysis

North America is expected to hold a significant position in the global neurodiagnostics market with the highest market share

The North America region is the dominant market for neurodiagnostics, driven by factors such as advanced healthcare infrastructure, high healthcare spending, widespread access to cutting-edge neurodiagnostic technologies, and a high prevalence of neurological diseases. This dominance is also supported by the presence of leading healthcare providers, manufacturers of diagnostic equipment, and ongoing advancements in research and development (R&D).

According to the Alzheimer's Association, nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. This rising incidence of neurological disorders in North America, including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, and multiple sclerosis, is a significant factor propelling the growth of the neurodiagnostics market. As the prevalence of neurological conditions is increasing, there is a greater need for accurate diagnostic tools.

North America is at the forefront of technological innovation in the neurodiagnostics market, with continuous advancements in diagnostic tools that improve both the accuracy and efficiency of neurological diagnoses. These innovations include AI-powered diagnostic tools and wearable EEG devices, which are transforming how neurological conditions are diagnosed and managed.

For instance, in November 2024, LVIS Corporation launched NeuroMatch Access, an artificial-intelligence (AI)-driven platform for electroencephalogram (EEG) data analysis in the US. The Silicon Valley, US-based company's platform, which received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2023, uses AI to review and interpret EEG signals by removing unwanted artifacts. EEG is used to measure the electrical activity of the brain and can aid in the diagnosis of conditions, including brain damage and epilepsy.

Competitive Landscape

Top companies in the neurodiagnostics market include GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., FUJIFILM Holdings, Thermo Fisher Scientific Inc., Compumedics Limited, Natus, Stratus, Canon Medical Systems USA, Inc., Nihon Kohden Corporation, and among others.

Key Developments

  • In April 2025, Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.
  • In October 2023, Ceribell, Inc. announced the commercial release of its new AI algorithm, ClarityPro, accompanying the availability of potential additional reimbursement for eligible Medicare patients. ClarityPro is an AI-based software algorithm within the Ceribell EEG system that analyzes EEG waveforms to diagnose electrographic status epilepticus (ESE).
  • In October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app called BeCare Neuro Link, the new mobile application is intended for the remote, objective, and comprehensive assessment of neurologic patients or those with potential neurologic conditions. It can be used for screening as-of-yet-undiagnosed neurologic conditions as well as monitoring the response to treatment for known neurologic disorders.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurodiagnostics market report delivers a detailed analysis with 62 key tables, more than 61 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Neurodiagnostics
      • 3.1.1.2. Rising Prevalence of Neurological Disorders
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Neurodiagnostic Procedures
      • 3.1.2.2. Complexity of Neurological Conditions
    • 3.1.3. Opportunity
      • 3.1.3.1. Integration with Digital Therapeutics
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics

5. Neurodiagnostics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Diagnostic Equipment*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Electroencephalogram (EEG)
    • 5.2.4. Magnetoencephalography (MEG)
    • 5.2.5. MRI (Magnetic Resonance Imaging)
    • 5.2.6. CT scan (Computed Tomography)
    • 5.2.7. PET Scan (Positron Emission Tomography)
    • 5.2.8. Sleep Monitoring Devices
    • 5.2.9. Electromyography (EMG) Devices
    • 5.2.10. Polysomnogram (PSG) Devices
    • 5.2.11. Others
  • 5.3. Reagents, Consumables & Accessories
    • 5.3.1. Electrodes
    • 5.3.2. Media
    • 5.3.3. Buffers
    • 5.3.4. Antibodies
    • 5.3.5. Solvents
    • 5.3.6. Others
  • 5.4. Software and Applications

6. Neurodiagnostics Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Epilepsy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Alzheimer's Disease
  • 6.4. Parkinson's Disease
  • 6.5. Multiple Sclerosis
  • 6.6. Sleep Disorders
  • 6.7. Headache Disorders
  • 6.8. Stroke
  • 6.9. Traumatic Brain Injury (TBI)
  • 6.10. Dementia
  • 6.11. Others

7. Neurodiagnostics Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neurology Clinics
  • 7.4. Diagnostic Laboratories
  • 7.5. Homecare Settings
  • 7.6. Others

8. Neurodiagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. GE HealthCare*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Siemens Healthineers AG
  • 10.3. Koninklijke Philips N.V.
  • 10.4. FUJIFILM Holdings
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Compumedics Limited
  • 10.7. Natus
  • 10.8. Stratus
  • 10.9. Canon Medical Systems USA, Inc.
  • 10.10. Nihon Kohden Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us